Arrowhead Research (ARWR) Gets a Buy Rating from Chardan Capital

By Jason Carr

Chardan Capital analyst Keay Nakae reiterated a Buy rating on Arrowhead Research (ARWRResearch Report) on February 8 and set a price target of $24.50. The company’s shares closed on Friday at $15.66.

According to TipRanks.com, Nakae is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -13.4% and a 29.1% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Arcturus Therapeutics Ltd, Alnylam Pharma, and Dicerna Pharma.

Currently, the analyst consensus on Arrowhead Research is a Strong Buy with an average price target of $23.13, which is a 47.7% upside from current levels. In a report released today, B.Riley FBR also reiterated a Buy rating on the stock with a $19 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $22.39 and a one-year low of $4.77. Currently, Arrowhead Research has an average volume of 1.69M.

Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.